Piper Sandler Lowers Amgen's Price Target Despite Long-Term Growth Potential
On May 14, Piper Sandler reduced its price target for Amgen (AMGN) to $427 from $432 while maintaining an Overweight rating. The firm highlighted long-term growth potential driven by rare disease products like Uplizna and Tepezza. A week earlier, Freedom Broker upgraded AMGN to Buy.
Tickers: $AMGN